Unveiling the immune infiltrate modulation in cancer and response to immunotherapy by MIXTURE - an enhanced deconvolution method

The accurate quantification of tumor-infiltrating immune cells turns crucial to uncover their role in tumor immune escape, to determine patient prognosis and to predict response to immune checkpoint blockade. Current state-of-the-art methods that quantify immune cells from tumor biopsies using gene expression data apply computational deconvolution methods that present multicollinearity and estimation errors resulting in the overestimation or underestimation of the diversity of infiltrating immune cells and their quantity. To overcome such limitations, we developed MIXTURE, a new ν-support vector regression-based noise constrained recursive feature selection algorithm based on validated immune cell molecular signatures. MIXTURE provides increased robustness to cell type identification and proportion estimation, outperforms the current methods, and is available to the wider scientific community. We applied MIXTURE to transcriptomic data from tumor biopsies and found relevant novel associations between the components of the immune infiltrate and molecular subtypes, tumor driver biomarkers, tumor mutational burden, microsatellite instability, intratumor heterogeneity, cytolytic score, programmed cell death ligand 1 expression, patients' survival and response to anti-cytotoxic T-lymphocyte-associated antigen 4 and anti-programmed cell death protein 1 immunotherapy.

[1]  Eytan Ruppin,et al.  Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma , 2018, Nature Medicine.

[2]  Ash A. Alizadeh,et al.  Determining cell-type abundance and expression from bulk tissues with digital cytometry , 2019, Nature Biotechnology.

[3]  M. Balzarini,et al.  Bedside Linear Regression Equations to Estimate Equilibrated Blood Urea , 2011 .

[4]  G. Getz,et al.  Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.

[5]  P. Laurent-Puig,et al.  Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression , 2016, Genome Biology.

[6]  P. Laurent-Puig,et al.  TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti–PD-1 in Lung Adenocarcinoma , 2018, Clinical Cancer Research.

[7]  Jeffrey W. Pollard,et al.  Macrophage Diversity Enhances Tumor Progression and Metastasis , 2010, Cell.

[8]  X. Shirley Liu,et al.  Revisit linear regression-based deconvolution methods for tumor gene expression data , 2017, Genome Biology.

[9]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[10]  A. Beckett,et al.  AKUFO AND IBARAPA. , 1965, Lancet.

[11]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Martin L. Miller,et al.  UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma , 2019, Cell.

[13]  H. Schreiber,et al.  Innate and adaptive immune cells in the tumor microenvironment , 2013, Nature Immunology.

[14]  Ash A. Alizadeh,et al.  Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.

[15]  D. Schadendorf,et al.  Tertiary lymphoid structures improve immunotherapy and survival in melanoma , 2020, Nature.

[16]  J. Szustakowski,et al.  Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden , 2018, The New England journal of medicine.

[17]  J. Sosman,et al.  Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2017, Cell.

[18]  E. D. de Vries,et al.  Tumor-associated macrophages in breast cancer: Innocent bystander or important player? , 2018, Cancer treatment reviews.

[19]  M. Hou,et al.  Altered monocyte differentiation and macrophage polarization patterns in patients with breast cancer , 2018, BMC Cancer.

[20]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[21]  Kaanan P. Shah,et al.  Integrated genomic profiling expands clinical options for patients with cancer , 2019, Nature Biotechnology.

[22]  S. Gabriel,et al.  Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.

[23]  L. Lynch,et al.  γδ T cells in cancer: a small population of lymphocytes with big implications , 2019, Clinical & translational immunology.

[24]  T. Chan,et al.  Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab , 2017, Cell.

[25]  Ajay Goel,et al.  Microsatellite instability in colorectal cancer. , 2010, Gastroenterology.

[26]  D. Altman,et al.  STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.

[27]  N. Samadi,et al.  Tumor microenvironment-mediated chemoresistance in breast cancer. , 2016, Breast.

[28]  Z. Stadler,et al.  Immunotherapy in colorectal cancer: rationale, challenges and potential , 2019, Nature Reviews Gastroenterology & Hepatology.

[29]  S. Leung,et al.  Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration , 2014, Breast Cancer Research.

[30]  N. Hacohen,et al.  Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.

[31]  Yu Wang,et al.  Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data , 2017, Genome Medicine.

[32]  Alberto Mantovani,et al.  Tumour-associated macrophages as treatment targets in oncology , 2017, Nature Reviews Clinical Oncology.

[33]  R. Bourgon,et al.  TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells , 2018, Nature.

[34]  J. Pollard,et al.  Immune cell promotion of metastasis , 2015, Nature Reviews Immunology.

[35]  J. Wolchok,et al.  Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.

[36]  Nijiati Aierken,et al.  Prognostic value of tumor-infiltrating Foxp3+ regulatory T cells in patients with breast cancer: a meta-analysis , 2017, Journal of Cancer.

[37]  Z. Trajanoski,et al.  Next-generation computational tools for interrogating cancer immunity , 2019, Nature Reviews Genetics.

[38]  P. Hegde,et al.  Top 10 Challenges in Cancer Immunotherapy. , 2020, Immunity.

[39]  Michael Peyton,et al.  Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. , 2015, Cancer discovery.

[40]  Z. Trajanoski,et al.  Quantifying tumor-infiltrating immune cells from transcriptomics data , 2018, Cancer Immunology, Immunotherapy.

[41]  A. Regev,et al.  Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma , 2019, Nature Medicine.

[42]  Z. Modrušan,et al.  Deconvolution of Blood Microarray Data Identifies Cellular Activation Patterns in Systemic Lupus Erythematosus , 2009, PloS one.

[43]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[44]  Renaud Gaujoux,et al.  CellMix: a comprehensive toolbox for gene expression deconvolution , 2013, Bioinform..

[45]  Laurence Zitvogel,et al.  The immune contexture in cancer prognosis and treatment , 2017, Nature Reviews Clinical Oncology.

[46]  M. Ceccarelli,et al.  RNA-Seq Signatures Normalized by mRNA Abundance Allow Absolute Deconvolution of Human Immune Cell Types , 2019, Cell reports.

[47]  Yamil D. Mahmoud,et al.  Targeting TMEM176B Enhances Antitumor Immunity and Augments the Efficacy of Immune Checkpoint Blockers by Unleashing Inflammasome Activation , 2019, Cancer cell.

[48]  A. Cesano nCounter® PanCancer Immune Profiling Panel (NanoString Technologies, Inc., Seattle, WA) , 2015, Journal of Immunotherapy for Cancer.

[49]  Jay Shendure,et al.  Classification and characterization of microsatellite instability across 18 cancer types , 2016, Nature Medicine.

[50]  D. Schadendorf,et al.  Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. , 2019, The New England journal of medicine.

[51]  Francisco Avila Cobos,et al.  Computational deconvolution of transcriptomics data from mixed cell populations , 2018, Bioinform..

[52]  Jennifer Couzin-Frankel,et al.  Breakthrough of the year 2013. Cancer immunotherapy. , 2013, Science.

[53]  Barbara B. Shih,et al.  Immune Cell Gene Signatures for Profiling the Microenvironment of Solid Tumors , 2018, Cancer Immunology Research.

[54]  P. Altevogt,et al.  Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors , 2004 .

[55]  A. Butte,et al.  xCell: digitally portraying the tissue cellular heterogeneity landscape , 2017, Genome Biology.

[56]  T. Chan,et al.  The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy , 2019, Nature Reviews Cancer.

[57]  H Nagura,et al.  CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. , 1998, Cancer research.

[58]  Brian Ruffell,et al.  Macrophages as regulators of tumour immunity and immunotherapy , 2019, Nature Reviews Immunology.